Eli Lilly has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization (MA) for its ulcerative colitis treatment, Mirikizumab.
Purdue University and the pharma company will create a scholarship program and renew their strategic research collaboration as part of the agreement.
England's cost-effectiveness watchdog has recommended Eli Lilly’s Verzenios treatment as an option for adjuvant treatment of certain forms of breast cancer.
The pharmaceutical firm will work with the health tech company to create a digital therapeutic intended for patients dealing with a breast cancer diagnosis.
The pharmaceutical company is partnering with Yseop to install the software company’s Augmented Analyst, designed to elevate and accelerate data analysis.
The 2022 edition of the Highly Potent Active Pharmaceutical Ingredients Summit (June 28 to 30 in Boston) will take on a range of topics, including safety.
A leader from the division of Eli Lilly explains the importance of driving greater trial inclusivity, and why collaboration is vital in making progress.
The two tech-focused firms are joining forces to work on technology solutions aimed at improving patient recruitment and enrollment for various studies.
The pharma firm is partnering with the decentralized research organization on a Phase III trial testing a long-acting antibody combination treatment.
With pharma firms seeking solutions to get products in the hands of patients faster, one company believes blockchain technology could provide answers.
The clinical research solutions firm is joining forces with pharma giant Eli Lilly to manage mobile research of the monoclonal antibody LY-CoV555.
Lilly will begin construction of a parenteral products-focused facility this year, suggesting that 462 new jobs will be created.
US FDA gives marketing authorization to Lilly’s oral medication for the acute treatment of migraines in adult patients, adding to its Emgality approval almost exactly a year ago.
US FDA updates Mylan’s ANDA to commercialize a generic of Lilly’s Alimta with a tentative approval, putting the company on course to enter the market in 2022.
So far in 2019, there has been significant activity in M&A, particularly on the larger scale, but can the pace continue for the rest of the year?
Courts continue to rule in favor of Lilly’s lung cancer treatment patent, as the District Court for Appeals concludes generic producers like Dr Reddy’s to be potentially infringing.
Eli Lilly acquires exclusive worldwide rights for non-opioid treatment for chronic pain from Centrexion through a licensing agreement.
After operating out of China for 19 years, Chi-Med’s CEO explains how the market has grown ‘very rapidly’ in the last four years.
Lilly France announced 250 positions will be cut from its Fegersheim site but will also invest €100m to update facilities over the coming years.
Eli Lilly will acquire Loxo for $8bn to gain access to treatments that target cancers dependent on single gene abnormalities.
Adimab, LLC is transferring its proprietary antibody discovery and optimization platform to Lilly research sites in San Diego and New York.
AstraZeneca has no competitive concerns about teaming with Eli Lilly to identify chronic kidney disease (CKD) targets.
WuXi PharmaTech will develop and manufacture a cardiovascular candidate for Eli Lilly in China through a strategic collaboration.
Despite expanding their in-house R&D facilities, both Pfizer and Eli Lilly say they remain committed to using CROs.
Eli Lilly and China biotech Innovent Biologics will collaborate to develop at least three cancer treatments over the next decade.
Novartis will close an OTC plant in Puerto Rico by 2019 and transfer manufacturing and packaging actives to sites in the US and facilities operated by Eli Lilly and Virbac.
The US FDA has published an import alert for an Australian manufacturing site of Eli Lilly after the agency found that its Cialis pills were tainted with the active ingredient of another popular ED (erectile dysfunction) drug -- Pfizer’s Viagra.
Big pharma employees are among the brightest minds in the world, and data released yesterday on their Wikipedia use shows their interests spread beyond drug development into lighter fare.
An online quiz about drug R&D has been criticised by economists who say its developer - Eli Lilly - is misinforming the public about the cost and time it takes to develop new medicines.
A Brazilian Court in Sao Paulo has ordered Eli Lilly pay about $450m for exposing former employees of its subsidiary to hazardous substances in a manufacturing facility operated between 1977 and 2003.
news from Interphex
The thin profit margins associated with relatively simple sterile products has led to a reluctance to invest in operations and shortages, according to an industry expert.
Performance monitoring should be applied equally to external manufacturing as internal operations, says Eli Lilly.
Lilly says another investment in its Indianapolis facility will add a second insulin cartridge-filling line and is driven by the increasing prevalence of diabetes.
Lilly's new Ireland plant is prep for pipeline products
Eli Lilly says plans for a new €330m ($444m) manufacturing facility in Ireland are in preparation for the launch of a range of its pipeline molecules.
News from Eli Lilly, Roche, and Merck – People on the move
in-PharmaTechnologist presents its round-up of the latest career moves within the pharmaceutical industry, including news from Eli Lilly, Roche, and Merck.
Appointments at Sanofi, GSK, Eli Lilly and Watson Pharmaceuticals – People on the move
in-PharmaTechnologist presents its latest round-up of movements in the pharma sector including appointments at Sanofi, GSK, Eli Lilly and Watson Pharmaceuticals.
Top 5 videos, podcasts & graphics on Outsourcing-Pharma
Outsourcing-Pharma presents five of our top audio-visual articles of 2010, including a timeline of Lilly’s outsourcing, the need for US capacity and why biomarkers are indispensible.
Appointments at Discovery Laboratories, Eli Lilly and Agios Pharmaceuticals – People on the move
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Discovery Laboratories, Eli Lilly and Agios Pharmaceuticals.
Parexel to support Lilly in Asia-Pacific; trials RFID temp monitoring system
Parexel has partnered with Eli Lilly and Company to establish a strategic relationship to support clinical development in the Asia-Pacific region.
Imclone closes US Erbitux plant
Imclone has closed the manufacturing facility in Branchburg, New Jersey where it produces the cancer drug Erbitux, according to reports in the US media.
Lilly’s Puerto Rico API plant issued with FDA warning letter
The FDA has issued Eli Lilly with a warning letter detailing a significant deviation from cGMP at its API production facility in Puerto Rico, which makes ingredients used in Humalog (insulin lispro), a diabetes treatment.
A new president of Eli Lilly USA and a resignation over disagreements at Caraco – People on the move
in-PharmaTechnologist presents its latest round up of appointments in the pharma sector, including a new president of Eli Lilly USA and a resignation over disagreements at Caraco.
Lilly to cut workforce 10% in bid to save $1bn by 2011
US drugmaker Eli Lilly plans to cut 5,500 jobs by 2011 as it prepares to enter what CEO John Lechleiter said will be “the most challenging period in [the] company’s history.”
Cerep predicts upturn in discovery services revenues
Demand for Cerep’s pharmacological profiling services picked up in the second quarter and it believes this, coupled to cost savings and commencement of delayed contracts, will help it improve in the second half of 2009.
Lilly to train Russian FDA
Eli Lilly is among the organisations partnering to provide training for the Rozdravnadzor, Russia’s equivalent of the FDA, which is seeking to improve its knowledge of manufacturing standards.
A former mayor joining Eli Lilly and new CEOs at three companies – People on the move
in-PharmaTechnologist presents its latest round up of appointments in the pharmaceutical sector, including a former mayor joining Eli Lilly and new CEOs at three companies.
Biosimilar bill could be "stake in the heart"
In a session chaired by at BIO 2009 John Lechleiter, CEO at Eli Lilly, speakers discussed patent reform, biosimilar bills and why certain options on the table could be a "stake in the heart" of the biotech industry.
Lilly & Amylin team up to create diabetes pen
Eli Lilly and Amylin Pharmaceuticals are jointly developing an exenatide once weekly pen device, which should provide a more convenient way for diabetics to treat themselves.
Altea inks deal to use Byetta with PassPort patch
The search for more convenient diabetes treatments continues, with Altea Therapeutics reaching a $46m agreement with Eli Lilly and Amylin to develop a transdermal patch administering Byetta.
Lilly seals cardiovascular R&D deal with Zydus
Eli Lilly’s pursuit of outsourcing deals continues unabated with the pharma major entering into a cardiovascular R&D collaboration with Zydus Cadila that has been described as a “new paradigm for global alliances”.